Liver disease

Questions discussed in this category

Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?

1 Answer available

To what extent does the degree of thrombocytopenia correlate with the severity of cirrhosis?

1 Answer available

Would you give a TPO agonist for thrombocytopenia in alcoholic cirrhosis?

1 Answer available

What is your preferred anticoagulant for acute portal vein thrombosis?

How does cirrhosis and/or underlying thrombophilia affect your decision?

1 Answer available

Is there a role for prednisolone over prednisone in rheumatic patients with hepatic impairment?

1 Answer available

How does the presence of nonalcoholic fatty liver disease (NAFLD) impact your choice of csDMARD for RA?

1 Answer available

Papers discussed in this category

Clin Pharmacokinet,

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Gut,

Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.

The New England journal of medicine, 2018-11-22

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2017-08-31

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Journal of clinical pharmacology, 2018-12

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.

N Engl J Med,

First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer.

Investigational new drugs, 2023 Apr 13

Brigatinib pharmacokinetics in patients with chronic hepatic impairment.

Case reports in oncology, 2021 Mar 01

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.

Related Topics